Physician profile
Yaakov Perlstein
NPI 1457936742
$1,725.35
in general payments reported to CMS, 2019-2025
28 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $674 · 2022: $251 · 2023: $271 · 2024: $156 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $264.68 | 2021-2024 | |
| Amgen INC. | $220.09 | 2021-2022 | |
| Lilly USA, LLC | $171.41 | 2021-2023 | Mounjaro |
| Incyte Corporation | $134.76 | 2021-2025 | Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $98.21 | 2021 | |
| Janssen Biotech, INC. | $92.32 | 2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $90.54 | 2022-2023 | Xospata, Xtandi |
| Glaxosmithkline, LLC. | $63.19 | 2025 | Ojjaara, Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $59.59 | 2022 | |
| Invivyd INC | $51.23 | 2025 | Pemgarda |
| Puma Biotechnology, INC. | $48.37 | 2021 | |
| Daiichi Sankyo INC. | $43.95 | 2025 | Injectafer |
| Abbvie INC. | $43.95 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $41.84 | 2022 | |
| Agios Pharmaceuticals, INC. | $34.95 | 2025 | Pyrukynd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.97 | 2021 | |
| Genentech USA, INC. | $25.08 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.15 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.94 | 2023 | Libtayo |
| Genzyme Corporation | $22.41 | 2021 | |
| Coherus Oncology, INC. | $22.03 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.76 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.04 | 2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $17.70 | 2021 | |
| Acceleron Pharma, INC. | $17.30 | 2021 | |
| Octapharma USA, INC. | $17.20 | 2025 | Octagam Immune Globulin (Human) |
| Sobi, INC | $15.97 | 2025 | |
| Celgene Corporation | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaakov Perlstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.